4GB Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Gossamer Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.64 |
| 52 Week High | US$1.46 |
| 52 Week Low | US$0.45 |
| Beta | 1.96 |
| 11 Month Change | -19.33% |
| 3 Month Change | -14.88% |
| 1 Year Change | -2.42% |
| 33 Year Change | -93.56% |
| 5 Year Change | -97.14% |
| Change since IPO | -96.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4GB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.2% | 0.8% | -1.3% |
| 1Y | -2.4% | -17.5% | 7.4% |
Return vs Industry: 4GB exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 4GB underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 4GB volatility | |
|---|---|
| 4GB Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4GB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4GB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 135 | Faheem Hasnain | www.gossamerbio.com |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.
Gossamer Bio, Inc. Fundamentals Summary
| 4GB fundamental statistics | |
|---|---|
| Market cap | €150.32m |
| Earnings (TTM) | -€68.35m |
| Revenue (TTM) | €100.48m |
1.4x
P/S Ratio-2.1x
P/E RatioIs 4GB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4GB income statement (TTM) | |
|---|---|
| Revenue | US$105.32m |
| Cost of Revenue | US$0 |
| Gross Profit | US$105.32m |
| Other Expenses | US$176.97m |
| Earnings | -US$71.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -68.03% |
| Debt/Equity Ratio | 364.4% |
How did 4GB perform over the long term?
See historical performance and comparison